Table 3.
Ocular adverse events
| Ocular adverse events | Cohort 1 + 2, N = 6 (%) | Cohort 3 + 4, N = 15 (%) |
|---|---|---|
| Anterior chamber cell | 0 (0.0) | 1 (6.7) |
| Cataract development/progression | 2 (33.3) | 6 (40.0) |
| Choroidal neovascularization | 0 (0.0) | 2 (13.3) |
| Corneal edema | 0 (0.0) | 1 (6.7) |
| Eye pain | 0 (0.0) | 4 (26.7) |
| Eye pruritus | 1 (16.7) | 2 (13.3) |
| IOP elevation | 0 (0.0) | 1 (6.7) |
| Intra/subretinal hemorrhage | 3 (50) | 8 (53.3) |
| Macular hole | 0 (0.0) | 1 (6.7) |
| Macular edema | 0 (0.0) | 3 (20.0) |
| Retinal tear | 0 (0.0) | 2 (13.3) |
| Subconjunctival hemorrhage | 0 (0.0) | 3 (20.0) |
| Subretinal fibrosis | 0 (0.0) | 1 (6.7) |
| Subretinal fluid | 0 (0.0) | 2 (13.3) |
| Vision blurred | 1 (16.7) | 1 (6.7) |
| Visual acuity reduced | 0 (0.0) | 3 (20.0) |
| Vitreous floaters | 0 (0.0) | 2 (13.3) |
| Vitreous hemorrhage | 0 (0.0) | 1 (6.7) |
IOP, intraocular pressure.